share_log

阿里健康：截至2024年9月30日止六個月中期業績公告

ALI HEALTH: ANNOUNCEMENT OF INTERIM RESULTSFOR THE SIX MONTHS ENDED SEPTEMBER 30, 2024

HKEX ·  Nov 13 18:17

Summary by Futu AI

阿里健康信息技術有限公司（「阿里健康」）公佈截至2024年9月30日止六個月的未經審核中期業績。報告期內，集團收入達人民幣14,273.7百萬元，同比增長10.2%；淨利潤額為人民幣769.0百萬元，同比增長72.8%；經調整淨利潤額達人民幣977.6百萬元，同比增長52.2%。淘天醫療健康品服務平台年化活躍消費者超過3億，天貓健康平台商品交易總額（「GMV」）實現同比高質量穩定增長。醫藥電商平台業務收入強勁增長67.5%，達到人民幣1,710.5百萬元。醫藥自營業務收入同比增長5.9%，至人民幣12,120.9百萬元。與集團簽約提供在線健康諮詢服務的執業醫師、執業藥師和營養師合計超23萬人。碼上放心平台與600多家行業領先藥企建立了深度合作關係。本集團未來將持續賦能「雲藥房」、「雲醫院」和「雲基建」戰略，為用戶提供優質高效的醫療健康服務。
阿里健康信息技術有限公司（「阿里健康」）公佈截至2024年9月30日止六個月的未經審核中期業績。報告期內，集團收入達人民幣14,273.7百萬元，同比增長10.2%；淨利潤額為人民幣769.0百萬元，同比增長72.8%；經調整淨利潤額達人民幣977.6百萬元，同比增長52.2%。淘天醫療健康品服務平台年化活躍消費者超過3億，天貓健康平台商品交易總額（「GMV」）實現同比高質量穩定增長。醫藥電商平台業務收入強勁增長67.5%，達到人民幣1,710.5百萬元。醫藥自營業務收入同比增長5.9%，至人民幣12,120.9百萬元。與集團簽約提供在線健康諮詢服務的執業醫師、執業藥師和營養師合計超23萬人。碼上放心平台與600多家行業領先藥企建立了深度合作關係。本集團未來將持續賦能「雲藥房」、「雲醫院」和「雲基建」戰略，為用戶提供優質高效的醫療健康服務。
Ali Health Technologies Co., Ltd. ("Ali Health") announced its unaudited interim performance for the six months ended September 30, 2024. During the reporting period, the group's revenue reached RMB 14,273.7 million, a year-on-year increase of 10.2%; net profit was RMB 769 million, a year-on-year increase of 72.8%; adjusted net profit reached RMB 977.6 million, a year-on-year increase of 52.2%. The Taikang Medical Health product service platform has an annual active consumer base of over 0.3 billion, and Tmall Health platform's total commodity trading volume (GMV) achieved stable growth of high quality year-on-year. The pharmaceutical e-commerce platform business revenue saw a strong growth of 67.5%, reaching RMB 1710.5 million. Self-operated pharmaceutical business revenue increased by 5.9% year-on-year to RMB...Show More
Ali Health Technologies Co., Ltd. ("Ali Health") announced its unaudited interim performance for the six months ended September 30, 2024. During the reporting period, the group's revenue reached RMB 14,273.7 million, a year-on-year increase of 10.2%; net profit was RMB 769 million, a year-on-year increase of 72.8%; adjusted net profit reached RMB 977.6 million, a year-on-year increase of 52.2%. The Taikang Medical Health product service platform has an annual active consumer base of over 0.3 billion, and Tmall Health platform's total commodity trading volume (GMV) achieved stable growth of high quality year-on-year. The pharmaceutical e-commerce platform business revenue saw a strong growth of 67.5%, reaching RMB 1710.5 million. Self-operated pharmaceutical business revenue increased by 5.9% year-on-year to RMB 12,120.9 million. Over 0.23 million practicing physicians, pharmacists, and nutritionists signed contracts with the group to provide online health consulting services. The MaShang Fangxin platform has established deep cooperative relationships with over 600 leading pharmaceutical companies in various industries. The group will continue to empower the "Cloud Pharmacy", "Cloud Hospital", and "Cloud Infrastructure" strategies in the future to provide users with high-quality and efficient medical health services.

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated